begin
novel
human
coronaviru
wuhan
china
trigger
worldwid
respiratori
diseas
outbreak
april
affect
million
peopl
worldwid
caus
death
date
antimalaria
drug
hydroxychloroquin
found
treatment
option
addit
support
treatment
oxygen
suppli
moder
case
extracorpor
membran
oxygen
critic
ill
patient
uniqu
medic
condit
also
investig
review
antibodi
therapi
might
immedi
strategi
emerg
prophylaxi
therapi
coronaviru
famili
virus
caus
rang
ill
human
common
cold
sever
form
like
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
danger
first
identifi
sever
infect
caus
coronaviru
aros
sar
epidem
china
second
outbreak
sever
infect
began
saudi
arabia
mer
third
outbreak
sever
ill
caus
novel
coronaviru
emerg
wuhan
citi
china
pandem
spread
countri
half
million
peopl
worldwid
infect
novel
coronaviru
april
least
confirm
death
million
affect
peopl
worldwid
everi
hour
number
increas
unit
state
record
maximum
posit
case
world
itali
spain
germani
franc
europ
continu
affect
death
respect
till
april
current
antimalaria
drug
hydroxychloroquin
found
treatment
option
nonrandom
studi
small
sampl
size
franc
show
hydroxychloroquin
plu
azithromycin
treatment
reduc
viral
load
patient
follow
studi
anoth
group
franc
report
hydroxychloroquin
plu
azithromycin
strong
antivir
activ
sever
affect
patient
clinic
studi
china
show
hydroxychloroquin
reduc
risk
progress
sever
ill
patient
chloroquin
hydroxychloroquin
highli
toxic
overdos
lead
rapid
onset
central
nervou
system
toxic
seizur
coma
cardiovascular
failur
hydroxychloroquin
receiv
emerg
use
author
fda
april
still
lot
question
optim
dose
treatment
coronaviru
virion
spheric
diamet
approxim
nm
reveal
cryoelectron
tomographi
cryoelectron
microscopi
corona
viral
genom
encod
four
main
structur
protein
name
surfac
spike
glycoprotein
membran
protein
small
envelop
e
glycoprotein
nucleocapsid
n
protein
protein
requir
provid
structur
complet
viral
particl
call
virion
spike
protein
glycoprotein
present
surfac
viru
crucial
entri
coronaviru
host
cell
contain
two
subunit
name
subunit
bind
receptor
surfac
host
cell
wherea
subunit
mediat
cell
membran
fusion
major
research
focus
identifi
antibodi
molecul
target
spike
protein
wuxi
biolog
develop
serum
therapi
could
use
first
aid
highrisk
patient
minireview
highlight
therapeut
intervent
may
potenti
prophylaxi
therapi
convalesc
plasma
therapi
consid
one
way
control
pandem
research
suggest
techniqu
decad
old
approach
use
earli
theori
simpl
person
recov
viral
infect
blood
collect
serum
separ
serum
contain
antigen
rais
antibodi
inject
newli
infect
person
combat
viru
antigen
antibodi
protein
produc
b
cell
immun
system
abl
bind
antigen
specif
molecul
present
pathogen
invad
human
system
directli
neutral
activ
immun
respons
base
previou
studi
report
treat
coronavirus
sar
mer
earli
administr
convalesc
plasma
patient
contain
rais
antibodi
possibl
reduc
spread
infect
mortal
shen
et
al
report
convalesc
plasma
transfus
may
benefici
treatment
critic
ill
patient
infect
get
approv
ethic
committe
shenzhen
third
peopl
hospit
administr
convalesc
plasma
contain
neutral
antibodi
critic
ill
patient
among
patient
discharg
hospit
patient
incub
period
day
casadeval
pirofski
highlight
risk
passiv
administr
convalesc
sera
fall
two
categori
serum
diseas
antibodydepend
enhanc
infect
serum
diseas
associ
transmiss
blood
infect
wherea
antibodydepend
enhanc
theoret
concern
antibodi
one
form
coronaviru
could
enhanc
infect
anoth
viral
strain
henc
import
identifi
human
monoclon
antibodi
neutral
crossneutr
antibodi
target
common
epitop
virus
offer
potenti
prevent
treatment
target
trimer
spike
glycoprotein
surfac
mediat
research
report
state
rbd
exhibit
significantli
higher
bind
affin
receptor
sarscov
rbd
could
block
bind
rbd
cell
thu
constrain
infect
host
cell
yushun
wan
colleagu
also
report
sequenc
similar
sarscov
includ
receptorbind
motif
rbm
directli
contact
strongli
signifi
use
receptor
andersen
human
monoclon
antibodi
neutral
research
report
declar
bind
conserv
epitop
spike
receptorbind
domain
crossneutr
crossreact
natur
show
antibodi
possibl
target
conserv
core
structur
receptor
bind
domain
henc
neutral
antibodi
reduc
cours
viru
action
host
defend
uninfect
host
expos
viru
therefor
target
rbd
amino
acid
treatment
help
scientist
develop
effect
therapeut
agent
treat
prevent
infect
amino
acid
mutat
recombin
rbd
differ
host
coronavirus
consid
associ
host
adapt
infect
across
speci
recent
research
indic
recombin
insert
cleavag
site
rbd
may
increas
infect
replic
capac
viru
ou
et
al
analyz
rbd
mutat
worldwid
report
mutant
identifi
high
posit
select
pressur
spread
investig
isol
collect
differ
part
world
compar
rbd
mutat
prototyp
strain
identifi
two
group
amino
acid
mutat
rbd
domain
similar
affin
group
higher
affin
group
higher
affin
group
rbd
mutat
posit
select
pressur
enhanc
infect
effici
henc
epidemiolog
data
mutat
surveil
import
reveal
exact
spread
rout
pandem
rbd
mutat
strain
countri
need
great
consider
find
therapeut
conclus
essenti
isol
rais
antibodi
diseas
recov
patient
region
wise
rais
antibodi
produc
larg
scale
treatment
patient
antibodi
could
provid
immedi
strategi
emerg
prophylaxi
therapi
altern
timeconsum
develop
vaccin
new
drug
underway
result
neutral
antibodi
may
use
prevent
infect
peopl
expos
hospit
staff
care
suspect
patient
may
also
use
earli
treatment
infect
individu
prevent
onset
seriou
diseas
reduc
chanc
spread
viru
expos
individu
